|
1
|
Ostrom QT, Cioffi G, Gittleman H, Patil N,
Waite K, Kruchko C and Barnholtz-Sloan JS: CBTRUS statistical
report: primary brain and other central nervous system tumors
diagnosed in the United States in 2012–2016. Neuro Oncol. 21 (Suppl
5):v1–v100. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lapointe S, Perry A and Butowski NA:
Primary brain tumours in adults. Lancet. 392:432–446. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Molinaro AM, Taylor JW, Wiencke JK and
Wrensch MR: Genetic and molecular epidemiology of adult diffuse
glioma. Nat Rev Neurol. 15:405–417. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Weller M, van den Bent M, Preusser M, Le
Rhun E, Tonn JC, Minniti G, Bendszus M, Balana C, Chinot O, Dirven
L, et al: EANO guidelines on the diagnosis and treatment of diffuse
gliomas of adulthood. Nat Rev Clin Oncol. 18:1702021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Stupp R, Hegi ME, Mason WP, Van Den Bent
MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B,
Belanger K, et al: Effects of radiotherapy with concomitant and
adjuvant temozolomide versus radiotherapy alone on survival in
glioblastoma in a randomised phase III study: 5-Year analysis of
the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
van Linde ME, Brahm CG, de Witt Hamer PC,
Reijneveld JC, Bruynzeel AME, Vandertop WP, van de Ven PM,
Wagemakers M, van der Weide HL, Enting RH, et al: Treatment outcome
of patients with recurrent glioblastoma multiforme: A retrospective
multicenter analysis. J Neurooncol. 135:183–192. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wen PY, Weller M, Lee EQ, Alexander BM,
Barnholtz-Sloan JS, Barthel FP, Batchelor TT, Bindra RS, Chang SM,
Chiocca EA, et al: Glioblastoma in adults: A society for
neuro-oncology (SNO) and European society of neuro-oncology (EANO)
consensus review on current management and future directions. Neuro
Oncol. 22:1073–1113. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Alexander BM and Cloughesy TF: Adult
glioblastoma. J Clin Oncol. 35:2402–2409. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Weller M and Le Rhun E: How did lomustine
become standard of care in recurrent glioblastoma? Cancer Treat
Rev. 87:1020292020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
McDuff SGR, Dietrich J, Atkins KM, Oh KS,
Loeffler JS and Shih HA: Radiation and chemotherapy for high-risk
lower grade gliomas: Choosing between temozolomide and PCV. Cancer
Med. 9:3–11. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Schmidt F, Fischer J, Herrlinger U, Dietz
K, Dichgans J and Weller M: PCV chemotherapy for recurrent
glioblastoma. Neurology. 66:587–589. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Happold C, Roth P, Wick W, Steinbach JP,
Linnebank M, Weller M and Eisele G: ACNU-based chemotherapy for
recurrent glioma in the temozolomide era. J Neurooncol. 92:45–48.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Brada M, Stenning S, Gabe R, Thompson LC,
Levy D, Rampling R, Erridge S, Saran F, Gattamaneni R, Hopkins K,
et al: Temozolomide versus procarbazine, lomustine, and vincristine
in recurrent high-grade glioma. J Clin Oncol. 28:4601–4608. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Parasramka S, Talari G, Rosenfeld M, Guo J
and Villano JL: Procarbazine, lomustine and vincristine for
recurrent high-grade glioma. Cochrane Database Syst Rev.
7:CD0117732017.PubMed/NCBI
|
|
15
|
Jutras G, Bélanger K, Letarte N, Adam JP,
Roberge D, Lemieux B, Lemieux-Blanchard É, Masucci L, Ménard C,
Bahary JP, et al: Procarbazine, lomustine and vincristine toxicity
in low-grade gliomas. Curr Oncol. 25:e33–e39. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Keogh RJ, Aslam R, Hennessy MA, Coyne Z,
Hennessy BT, Breathnach OS, Grogan L and Morris PG: One year of
procarbazine lomustine and vincristine is poorly tolerated in low
grade glioma: A real world experience in a national neuro-oncology
centre. BMC Cancer. 21:1402021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Park SB, Goldstein D, Krishnan AV, Lin CS,
Friedlander ML, Cassidy J, Koltzenburg M and Kiernan MC:
Chemotherapy-induced peripheral neurotoxicity: A critical analysis.
CA Cancer J Clin. 63:419–437. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang F, Zhou F, Kruh GD and Gallo JM:
Influence of blood-brain barrier efflux pumps on the distribution
of vincristine in brain and brain tumors. Neuro Oncol.
12:1043–1049. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim SH, Yoo H, Chang JH, Kim CY, Chung DS,
Kim SH, Park SH, Lee YS and Yang SH: Procarbazine and CCNU
chemotherapy for recurrent glioblastoma with MGMT promoter
methylation. J Korean Med Sci. 33:e1672018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vesper J, Graf E, Wille C, Tilgner J,
Trippel M, Nikkhah G and Ostertag C: Retrospective analysis of
treatment outcome in 315 patients with oligodendroglial brain
tumors. BMC Neurol. 9:332009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Webre C, Shonka N, Smith L, Liu D and De
Groot J: PC or PCV, that is the question: Primary anaplastic
oligodendroglial tumors treated with procarbazine and CCNU with and
without vincristine. Anticancer Res. 35:5467–5472. 2015.PubMed/NCBI
|
|
22
|
Yang SH, Hong YK, Yoon SC, Kim BS, Lee YS,
Lee TK, Lee KS, Jeun SS, Kim MC and Park CK: Radiotherapy plus
concurrent and adjuvant procarbazine, lomustine, and vincristine
chemotherapy for patients with malignant glioma. Oncol Rep.
17:1359–1364. 2007.PubMed/NCBI
|
|
23
|
Cha JY, Park JS, Hong YK, Jeun SS and Ahn
S: Impact of body mass index on survival outcome in patients with
newly diagnosed glioblastoma: A retrospective single-center study.
Integr Cancer Ther. 20:15347354219912332021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Trestini I, Carbognin L, Bonaiuto C,
Tortora G and Bria E: The obesity paradox in cancer: Clinical
insights and perspectives. Eat Weight Disord. 23:185–193. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Seystahl K, Hentschel B, Loew S, Gramatzki
D, Felsberg J, Herrlinger U, Westphal M, Schackert G, Thon N,
Tatagiba M, et al: Bevacizumab versus alkylating chemotherapy in
recurrent glioblastoma. J Cancer Res Clin Oncol. 146:659–670. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cai Y, Jiang YG, Wang M, Jiang ZH and Tan
ZG: A comparative study of the effectiveness and safety of combined
procarbazine, lomustine, and vincristine as a therapeutic method
for recurrent high-grade glioma: A protocol for systematic review
and meta-analysis. Medicine (Baltimore). 99:e222382020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Toft A, Urup T, Christensen IJ, Michaelsen
SR, Lukram B, Grunnet K, Kosteljanetz M, Larsen VA, Lassen U,
Broholm H and Poulsen HS: Biomarkers in recurrent grade III glioma
patients treated with bevacizumab and irinotecan. Cancer Invest.
36:165–174. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wick W and Winkler F: Regimen of
procarbazine, lomustine, and vincristine versus temozolomide for
gliomas. Cancer. 124:2674–2676. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tabouret E, Reyes-Botero G, Dehais C,
Daros M, Barrie M, Matta M, Petrirena G, Autran D, Duran A, Bequet
C, et al: Relationships between dose intensity, toxicity, and
outcome in patients with oligodendroglial tumors treated with the
PCV regimen. Anticancer Res. 35:2901–2908. 2015.PubMed/NCBI
|
